MYH2 Gene

MYH2 Gene

Overview

The MYH2 gene encodes myosin heavy chain 2 (MyHC-IIa), a fast-twitch skeletal muscle myosin that is essential for muscle contraction. MYH2 is one of four adult skeletal muscle myosin heavy chain genes (MYH1, MYH2, MYH4, MYH7) that encode proteins critical for force generation in skeletal muscle fibers. Mutations in MYH2 cause myosin storage myopathy (IBM3), congenital myopathy with ophthalmoplegia, and progressive external ophthalmoplegia (PEO). While primarily considered a neuromuscular disorder gene, the study of MYH2-related myopathies provides insights into muscle homeostasis, protein aggregation, and cellular quality control mechanisms that are relevant to broader neurodegenerative processes.

MYH2 Gene

Overview

The MYH2 gene encodes myosin heavy chain 2 (MyHC-IIa), a fast-twitch skeletal muscle myosin that is essential for muscle contraction. MYH2 is one of four adult skeletal muscle myosin heavy chain genes (MYH1, MYH2, MYH4, MYH7) that encode proteins critical for force generation in skeletal muscle fibers. Mutations in MYH2 cause myosin storage myopathy (IBM3), congenital myopathy with ophthalmoplegia, and progressive external ophthalmoplegia (PEO). While primarily considered a neuromuscular disorder gene, the study of MYH2-related myopathies provides insights into muscle homeostasis, protein aggregation, and cellular quality control mechanisms that are relevant to broader neurodegenerative processes.

<div class="infobox infobox-gene">
<table>
<tr><th>Gene Symbol</th><td>MYH2</td></tr>
<tr><th>Full Name</th><td>Myosin Heavy Chain 2</td></tr>
<tr><th>Chromosomal Location</th><td>17p13.1</td></tr>
<tr><th>NCBI Gene ID</th><td>4620</td></tr>
<tr><th>OMIM</th><td>160740</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000141349</td></tr>
<tr><th>UniProt ID</th><td>Q9Y2H5</td></tr>
<tr><th>Associated Diseases</th><td>Myosin Storage Myopathy (IBM3), Congenital Myopathy with Ophthalmoplegia, Progressive External Ophthalmoplegia (PEO)</td></tr>
</table>
</div>

Function

MYH2 encodes the myosin heavy chain 2 (MyHC-IIa) protein, which is a member of the class II conventional myosin family. Myosin heavy chains are large motor proteins that generate mechanical force through ATP-dependent interaction with actin filaments. In skeletal muscle, myosin functions as a heterohexamer composed of two myosin heavy chains and two pairs of non-identical myosin light chains.

Protein Structure

The MYH2 protein (approximately 2,240 amino acids) contains several conserved domains [@pie2020]:

Physiological Function

MYH2 is specifically expressed in fast-twitch type 2a muscle fibers, which are characterized by:

• Rapid contraction: Type 2a fibers contract 2-3 times faster than slow type 1 fibers
• High glycolytic capacity: Primarily use glycolysis for ATP production
• Intermediate fatigue resistance: More resistant to fatigue than type 2b fibers but less than type 1
• Oxidative metabolism: Contain more mitochondria than type 2b fibers

Expression Pattern

MYH2 expression is restricted to skeletal muscle tissue:

• Skeletal muscle: Highest expression in fast-twitch skeletal muscle
• Extraocular muscles: Highly expressed in muscles controlling eye movements
• Diaphragm: Contains significant proportion of type 2a fibers
• Developmental expression: MYH2 is expressed during late fetal development and becomes the predominant MyHC in adult skeletal muscle

Disease Associations

Myosin Storage Myopathy (IBM3)

Myosin storage myopathy (also known as Inclusion Body Myopathy 3, IBM3) is caused by heterozygous mutations in MYH2 [@tajsharghi2007]. This disorder is characterized by:

• Onset: Childhood to early adulthood
• Progressive muscle weakness: Affecting proximal muscles, particularly quadriceps
• Myosin accumulation: Intracellular deposits of myosin in muscle fibers
• Ophthalmoplegia: Variable involvement of eye muscles
• Autosomal dominant inheritance: Most cases show dominant inheritance

Congenital Myopathy with Ophthalmoplegia

Recessive mutations in MYH2 cause a severe form of congenital myopathy characterized by [@lorenzoni2007]:

• Early onset: Symptoms present at birth or in early infancy
• Generalized muscle weakness: Hypotonia and motor developmental delays
• External ophthalmoplegia: Inability to move eyes fully
• Respiratory involvement: May require respiratory support
• Feeding difficulties: Often requires nutritional support

Progressive External Ophthalmoplegia (PEO)

Progressive external ophthalmoplegia is associated with both dominant and recessive MYH2 mutations [@lawlor2011]:

• Adult onset: Typically presents in adolescence or early adulthood
• Isolated eye muscle involvement: Primarily affects extraocular muscles
• Ptosis: Drooping of upper eyelids
• Slow progression: Disease progression over decades
• May be associated with systemic features: Including mild proximal weakness

Molecular Mechanisms

Pathogenesis of MYH2-Related Myopathies

The molecular mechanisms underlying MYH2-related myopathies involve several interconnected pathways:

Relationship to Neurodegenerative Processes

While MYH2 is not a primary neurodegenerative disease gene, the mechanisms of MYH2-related myopathies share features with broader neurodegenerative processes:

• Protein aggregation: Similar to amyloid-beta in Alzheimer's disease, tau in tauopathies, and alpha-synuclein in Parkinson's disease
• Autophagy impairment: Common theme in many neurodegenerative conditions
• Mitochondrial dysfunction: Central to Parkinson's disease and other neurodegenerative disorders
• Cellular quality control failure: Ubiquitin-proteasome system dysfunction seen in multiple neurodegenerative diseases

Diagnosis

Genetic Testing

MYH2 mutations can be identified through:

• Sequencing: Targeted MYH2 sequencing or panel testing
• Whole exome sequencing: For unknown causes of congenital myopathy
• Deletion/duplication analysis: To detect larger genomic alterations

Muscle Biopsy

Key histological findings in MYH2-related myopathies include:

• Type 2 fiber atrophy: Selective loss or atrophy of type 2 fibers
• Myosin accumulation: Intracellular aggregates positive for myosin staining
• Central nuclei: Increased number of centralized nuclei in muscle fibers
• Fiber size variation: Heterogeneous fiber diameters

Imaging

Muscle MRI can reveal characteristic patterns of muscle involvement [@daignault2020]:

• Selective involvement: Quadriceps muscles most affected
• Symmetric pattern: Bilateral, symmetric muscle involvement
• Fat replacement: Progressive fatty infiltration of affected muscles

Treatment and Management

Current Therapies

There is currently no disease-modifying treatment for MYH2-related myopathies. Management focuses on:

• Physical therapy: Maintaining muscle strength and function
• Respiratory support: For patients with diaphragmatic involvement
• Ophthalmologic management: For ptosis and ophthalmoplegia
• Nutritional support: For feeding difficulties in congenital cases

Research Directions

Emerging therapeutic approaches include:

• Gene therapy: Viral vector delivery of wild-type MYH2
• Antisense oligonucleotides: To modulate MYH2 expression
• Autophagy enhancers: To improve clearance of aggregated proteins
• Small molecule stabilizers: To stabilize mutant myosin proteins

Animal Models

Several animal models have been developed to study MYH2 function and disease:

• Mouse models: Myh2 knockout mice show muscle fiber type switching
• Zebrafish models: Knockdown studies reveal developmental muscle defects
• Cell culture models: Myotubes from patient-derived iPSCs

Key Publications

See Also

• [Muscle Contraction Pathway](/mechanisms/muscle-contraction-pathway)
• [Skeletal Muscle Development](/mechanisms/skeletal-muscle-development)
• [Protein Aggregation in Neurodegeneration](/mechanisms/protein-aggregation)
• [Autophagy Pathway](/mechanisms/autophagy-pathway)
• [Neuromuscular Junction](/mechanisms/neuromuscular-junction)

External Links

• [NCBI Gene: MYH2](https://www.ncbi.nlm.nih.gov/gene/4620)
• [OMIM: 160740](https://www.omim.org/entry/160740)
• [UniProt: Q9Y2H5](https://www.uniprot.org/uniprot/Q9Y2H5)
• [Ensembl: ENSG00000141349](https://www.ensembl.org/Homo_species/Gene/Summary?g=MYH2)
• [Human Protein Atlas: MYH2](https://www.proteinatlas.org/ENSG00000141349-MYH2)

References

agrawal2007, Myosin storage myopathy associated with heterozygous mutations in MYH2 (2007)
boodine2011, Clinical heterogeneity in myosin storage myopathy (2011)
chaabane2020, MYH2 expression in neuromuscular disorders (2020)
daigner2020, Muscle MRI in MYH2-related myopathies (2020)
engel2020, Congenital myopathies: new strategies for treatment (2020)
lawlor2011, Novel MYH2 mutations causing progressive external ophthalmoplegia (2011)
lorenzoni2007, Congenital myopathy with MYH2 mutation (2007)
martone2019, MYH2 in extraocular muscle myopathies (2019)
mittal2018, Novel MYH2 mutations causing congenital myopathy (2018)
muntoni2003, Congenital myopathies: clinical features and diagnosis (2003)
nielsen2020, Skeletal muscle regeneration and myosin heavy chain switching (2020)
pie2020, Skeletal muscle myosin heavy chain genes (2020)
potter2019, Myosin head and tail domains in force generation (2019)
raju2021, MYH2-related myopathies: genotype-phenotype correlation (2021)
schiaffino2019, Myosin heavy chain isoforms in skeletal muscle development (2019)
stajJM2009, MYH2 gene mutations in autosomal recessive myopathy (2009)
tajsharghi2007, MYH2 mutations cause myosin storage myopathy (2007)
uniprot, Uniprot Q9Y2H5 - MYH2 Human [1](https://www.uniprot.org/uniprot/Q9Y2H5)
zhao2022, The role of myosin heavy chains in muscle disease (2022)

Pathway Diagram

The following diagram shows the key molecular relationships involving MYH2 Gene discovered through SciDEX knowledge graph analysis: